Relative bioavailability of tizanidine hydrochloride capsule formulation compared with capsule contents administered in applesauce: A single-dose, open-label, randomized, two-way, crossover study in fasted healthy adult subjects

Clinical Therapeutics

Volumn 30, Issue 12, 2008, Pages 2263-2271

  Henney III, Herbert R ^a   Fitzpatrick, Anthony ^b   Stewart, Johnston ^c   Runyan, Jacob D ^a  

^a ACORDA THERAPEUTICS INC   (United States)

^b ELAN PHARMACEUTICALS   (United States)

^c MDS Inc   (Canada)

Author keywords

formulation; pharmacokinetic; spasticity; tizanidine

Indexed keywords

TIZANIDINE;

ADULT; APPLE; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG FATALITY; DRUG FORMULATION; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; FOOD; FOOD DRUG INTERACTION; HEADACHE; HUMAN; INFECTION; LABORATORY TEST; MALE; NORMAL HUMAN; PAIN; PHASE 1 CLINICAL TRIAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TASTE DISORDER; TASTE PERVERSION; THINKING; THIRST; TOOTH DISEASE; VITAL SIGN; XEROSTOMIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADRENERGIC ALPHA-AGONISTS; ADULT; AREA UNDER CURVE; ASTHENIA; BIOLOGICAL AVAILABILITY; BLOOD PRESSURE; CAPSULES; CLONIDINE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FASTING; FEMALE; FOOD; FOOD-DRUG INTERACTIONS; HALF-LIFE; HUMANS; MALE; MALUS; MIDDLE AGED; RECEPTORS, ADRENERGIC, ALPHA-2; YOUNG ADULT;

EID: 58249136520     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.12.014     Document Type: Article

References (39)

1. Zanaflex (tizanidine hydrochloride) capsules and tablets [prescribing information]. Hawthorne, NY: Acorda Therapeutics, Inc; 2006.
2. (February 5, 2008). http://www.fda.gov/medwatch/safety/2006/Jul_PIs/Zanaflex_PI.pdf Accessed
3. Wagstaff A.J., and Bryson H.M. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 53 (1997) 435-452
4. Davies J. Selective depression of synaptic transmission of spinal neurones in the cat by a new centrally acting muscle relaxant, 5-chloro-4-(2-imidazolin-2-yl-amino)-2, 1,3-benzothiodazole (DS103-282). Br J Pharmacol. 76 (1982) 473-481
5. Collingridge G.L., and Davies J. Reversible effects of tetanus toxin on striatal-evoked responses and [3H]-gammaaminobutyric acid release in the rat substantia nigra. Br J Pharmacol. 76 (1982) 403-411
6. Smith C., Birnbaum G., Carter J.L., et al., US Tizanidine Study Group. Tizanidine treatment of spasticity caused by multiple sclerosis: Results of a double-blind, placebocontrolled trial. Neurology 44 Suppl 9 (1994) S34-S42 discussion S42-S43
7. The United Kingdom Tizanidine Trial Group. A doubleblind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology. 44 Suppl 9 (1994) S70-S78
8. Nance P.W., Bugaresti J., Shellenberger K., et al., North American Tizanidine Study Group. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. Neurology 44 Suppl 9 (1994) S44-S51 discussion S51-S52
9. Nance P.W., Sheremata W.A., Lynch S.G., et al. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Arch Neurol. 54 (1997) 731-736
10. Lapierre Y., Bouchard S., Tansey C., et al. Treatment of spasticity with tizanidine in multiple sclerosis. Can J Neurol Sci. 14 Suppl 3 (1987) 513-517
11. Lataste X., Emre M., Davis C., and Groves L. Comparative profile of tizanidine in the management of spasticity. Neurology. 44 Suppl 9 (1994) S53-S59
12. Tse F.L., Jaffe J.M., and Bhuta S. Pharmacokinetics of orally administered tizanidine in healthy volunteers. Fundam Clin Pharmacol. 1 (1987) 479-488
13. Mathias C.J., Luckitt J., Desai P., et al. Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury. J Rehabil Res Dev. 26 (1989) 9-16
14. Emre M., Leslie G.C., Muir C., et al. Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud). J Neurol Neurosurg Psychiatry. 57 (1994) 1355-1359
15. Shah J., Wesnes K.A., Kovelesky R.A., and Henney III H.R. Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers. Clin Ther. 28 (2006) 1308-1317
16. Roberts R.C., Part N.J., Pokorny R., et al. Pharmacokinetics and pharmacodynamics of tizanidine. Neurology 44 Suppl 9 (1994) S29-S31
17. Granfors M.T., Backman J.T., Laitila J., and Neuvonen P.J. Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. Br J Clin Pharmacol. 57 (2004) 349-353
18. Granfors M.T., Backman J.T., Neuvonen M., et al. Fluvoxamine drastically increases concentrations and effects of tizanidine: A potentially hazardous interaction. Clin Pharmacol Ther. 75 (2004) 331-341
19. Granfors M.T., Backman J.T., Neuvonen M., and Neuvonen P.J. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther. 76 (2004) 598-606
20. Backman J.T., Karjalainen M.J., Neuvonen M., et al. Rofecoxib is a potent inhibitor of cytochrome P450 1A2: Studies with tizanidine and caffeine in healthy subjects. Br J Clin Pharmacol. 62 (2006) 345-357
21. Backman J.T., Granfors M.T., and Neuvonen P.J. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: Studies with tizanidine and caffeine. Eur J Clin Pharmacol. 62 (2006) 451-461
22. Kirshblum S., Johnston M.V., Brown J., et al. Predictors of dysphagia after spinal cord injury. Arch Phys Med Rehabil. 80 (1999) 1101-1105
23. Abel R., Ruf S., and Spahn B. Cervical spinal cord injury and deglutition disorders. Dysphagia. 19 (2004) 87-94
24. Prosiegel M., Schelling A., and Wagner-Sonntag E. Dysphagia and multiple sclerosis. Int MS J. 11 (2004) 22-31
25. Henney III H.R., and Runyan J.D. A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients. Int J Clin Pract. 62 (2008) 314-324
26. Henney III H.R., and Shah J. Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: A singledose, randomized, open-label, crossover study in healthy subjects. Clin Ther. 29 (2007) 661-669
27. 1983 Metropolitan height and weight tables. Stat Bull Metrop Life Found 64 (1983) 3-9
28. European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation-World Health Organization. Guideline for Good Clinical Practice ICH Topic E6.
29. (September 6, 2008). http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf Accessed
30. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects.
31. (September 6, 2008). http://www.who.int/bulletin/archives/79(4)373.pdf Accessed
32. Department of Health and Human Services. Coding Symbols for Thesaurus of Adverse Reaction Terms. 5th ed. (1995), US Department of Commerce, National Technical Information Service, Rockville, Md
33. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); January 2001.
34. (April 19, 2007). http://www.fda.gov/cder/guidance/3616fnl.pdf Accessed
35. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); March 2003.
36. (April 17, 2007). http://www.fda.gov/cder/guidance/5356fnl.pdf Accessed
37. Kamen L., Henney III H.R., and Runyan J.D. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Curr Med Res Opin. 24 (2008) 425-439
38. Taittonen M., Räty H., Kirvelä O., et al. The metabolic effects of oral tizanidine in healthy volunteers. Acta Anaesthesiol Scand. 39 (1995) 628-632
39. Granfors M.T., Backman J.T., Laitila J., and Neuvonen P.J. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clin Pharmacol Ther. 78 (2005) 400-411